2. Search Result
Search Result
Results for "

peripheral tissues

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0415
    Fluocinolone (Acetonide)
    1 Publications Verification

    		 Glucocorticoid Receptor Wnt Inflammation/Immunology Endocrinology
    Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015) .
    Fluocinolone (Acetonide)
  • HY-P3160C
    Fibronectin, bovine plasma

    		Biochemical Assay Reagents Infection
    Fibronectin, bovine plasma is a fibronectin derived from bovine plasma. Fibronectin is an extracellular matrix protein that is upregulated and essential in many developmental processes, and also exists in the pathological progression of tissues and wound healing. Fibronectin specifically binds to a large number of molecules, including other components of the extracellular matrix, signaling molecules and cell adhesion molecules. The interaction between cells and fibronectin leads to bidirectional crosstalk, which regulates cell functions and induces cell-dependent changes in the extracellular matrix. Fibronectin, bovine plasma inhibits the production of bovine leukemia virus (BLV) p24 core protein in naturally infected bovine peripheral blood mononuclear cells .
    Fibronectin, bovine plasma
  • HY-160141
    Catadegbrutinib

    BGB-16673; BTK-IN-29

    		 PROTACs Btk NF-κB Inflammation/Immunology Cancer
    BGB-16673 (BGB-16673) is an orally active, selective BTK PROTAC degrader (IC50=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .
    Catadegbrutinib
  • HY-P4154
    Bevonescein

    ALM-488

    		 Fluorescent Dye Neurological Disease Cancer
    Bevonescein (ALM-488) is a fluorescein-conjugated peptide that facilitates the targeted delivery of a fluorescent moiety (5-FAM (HY-66022)) to nerves after intravenous (IV) administration. Bevonescein binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves (Ex/Em = 480/530 nm) .
    Bevonescein
  • HY-101176
    2-Iodomelatonin
    2 Publications Verification

    		 Melatonin Receptor Cancer
    2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 over MT2 . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .
    2-Iodomelatonin
  • HY-B1016
    Trapidil

    AR-12008

    		 PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor Cardiovascular Disease Neurological Disease
    Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury .
    Trapidil
  • HY-173527
    PSSI-51

    		Mitochondrial Metabolism Metabolic Disease
    PSSI-51 is an orally active, peripherally selective inhibitor of succinyl-CoA:3-ketoacid-CoA transferase (SCOT). PSSI-51 inhibits SCOT activity in peripheral tissues (such as muscle and kidney) but does not affect SCOT activity in brain tissue. PSSI-51 reduces ketone body oxidation by inhibiting SCOT, thereby improving obesity-related hyperglycemia. PSSI-51 can be used in the study of type 2 diabetes (T2D) and has the potential to improve obesity-related metabolic disorders .
    PSSI-51
  • HY-17657
    Androst-5-enediol sulfate sodium

    5-Androstenediol 3-sulfate sodium

    		 Drug Intermediate Metabolic Disease
    Androst-5-enediol sulfate (5-Androstenediol 3-sulfate) sodium salt is an adrenal Δ5-steroid sulfate that synthesized by zona reticularis of adrenal depending on the lyase and Cytochrome b5 type A (CYB5A) activity. Androst-5-enediol sulfate sodium salt is a precursor hormone and can be desulfated to produce more potent androgens, including testosterone, in peripheral tissues like skin and liver. The serum level of Androst-5-enediol sulfate sodium salt has an age-related increase .
    Androst-5-enediol sulfate sodium
  • HY-150701
    INCB13739

    		Glucocorticoid Receptor Mineralocorticoid Receptor 11β-HSD Metabolic Disease
    INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
    INCB13739
  • HY-14370
    LX2931

    		LPL Receptor Others Inflammation/Immunology
    LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the study of autoimmune diseases, especially rheumatoid arthritis .
    LX2931
  • HY-E70074
    Monoamine oxidase, plasma

    		Monoamine Oxidase Neurological Disease
    Monoamine oxidase (EC 1.4.3.4) is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions .
    Monoamine oxidase, plasma
  • HY-P1106A
    K41498 TFA

    		CFTR Cardiovascular Disease
    K41498 TFA is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 TFA inhibits cAMP accumulation in cells expressing CRF2. K41498 TFA antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 TFA undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues .
    K41498 TFA
  • HY-143792
    HTT-D3

    		Huntingtin P-glycoprotein Neurological Disease
    HTT-D3 is an orally active, blood-brain barrier penetrant splicing modulator of huntingtin (HTT). HTT-D3 promotes the inclusion of a pseudo-exon containing a premature termination codon into HTT pre-mRNA, triggers nonsense-mediated mRNA degradation and reduces HTT protein levels. HTT-D3 induces dose-dependent, comparable reductions in mutant HTT protein in both the brain and peripheral tissues of transgenic mouse models. HTT-D3 can be used for the research of Huntington's disease .
    HTT-D3
  • HY-P1106
    K41498

    		CRFR Cardiovascular Disease
    K41498 is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 inhibits cAMP accumulation in cells expressing CRF2. K41498 antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues .
    K41498
  • HY-P5640
    Tritrpticin

    		Bacterial Parasite Infection
    Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .
    Tritrpticin
  • HY-P10473
    CPN-351

    		Neuromedin U Receptor (NMUR) Inflammation/Immunology
    CPN-351 (compound 9a), a pentapeptide, is a selective antagonist of human NMUR1 with a pA2 of 7.35. The antagonistic effect of CPN-351 on human NMUR1 is 10 times higher than that on NMUR2. CPN-351 can be used in the study of inflammation .
    CPN-351
  • HY-122331
    Norbormide

    		Environmental Pollutants Calcium Channel Cardiovascular Disease
    Norbormide, a rodenticide, is a calcium entry blocker with a selective vasoconstrictor activity. Norbormide shows species- and tissue-specific, endothelium independent, and is restricted to the peripheral arteries of rat .
    Norbormide
  • HY-U00259
    BM152054

    		PPAR Metabolic Disease
    BM152054 is a potent PPARgamma-activator. BM152054 can promote glucose utilization in peripheral tissues by enhancing insulin action .
    BM152054
  • HY-121311
    Metrenperone

    		Serotonin Transporter Adrenergic Receptor Cardiovascular Disease
    Metrenperone is an inhibitor for 5-HT2 receptor. Metrenperone exhibits α1 and α2 antagonist activity as well as anti-H1 and anti-dopaminergic efficacy. Metrenperone can lower the blood pressure, enhances bradycardia in peripheral ischemia, inhibits serotonin-induced platelet aggregation, and antagonizes serotonin-mediated vasoconstriction. Metrenperone promotes the repair of acutely damaged collagen tissue .
    Metrenperone
  • HY-165478
    FCE 28260

    		5 alpha Reductase Endocrinology
    FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH) .
    FCE 28260
  • HY-B1016R
    Trapidil (Standard)

    AR-12008 (Standard)

    		 Reference Standards PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor Cardiovascular Disease Cancer
    Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.
    Trapidil (Standard)
  • HY-127023
    Eicosapentaenoyl serotonin

    EPA-5-HT

    		 Endogenous Metabolite FAAH Interleukin Related Tyrosine Hydroxylase Metabolic Disease
    Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
    Eicosapentaenoyl serotonin
  • HY-N8693
    Withanoside IV

    		COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV Infection Neurological Disease
    Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
    Withanoside IV
  • HY-P10110
    retro-inverso TAT-Beclin 1 (D-amino acid)

    		Autophagy Neurological Disease
    retro-inverso TAT-Beclin 1 D-amino acid is has higher activity and resistance to proteolytic degradation in vivo compared to L-amino acids peptide. TAT-Beclin 1 can induce autophagy in peripheral tissues in adult mice as well as in the central nervous system of neonatal mice .
    retro-inverso TAT-Beclin 1 (D-amino acid)
  • HY-N2304A
    Methyl-6-alpha-Naltrexol

    		Opioid Receptor Inflammation/Immunology
    Methyl-6-alpha-Naltrexol is a metabolite of Methylnaltrexone (MNTX). Methylnaltrexone is a selective mu-opioid receptor antagonist and functions as a peripherally acting receptor antagonist in tissues of the gastrointestinal tract .
    Methyl-6-alpha-Naltrexol
  • HY-162511
    IP2015

    		Dopamine Transporter Serotonin Transporter Others
    IP2015 is an inhibitor for monoamine reuptake, that inhibits the reuptake of dopamine, serotonin (5-HT), and noradrenaline. IP2015 increases release of central dopamine and peripheral nitric oxide (NO), causes the NO-mediated relaxation of erectile tissue, and thus induces erection in rat model .
    IP2015
  • HY-144126
    S1P1 agonist 5

    		LPL Receptor Inflammation/Immunology
    S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) .
    S1P1 agonist 5
  • HY-P1544
    Cerebellin

    		Endogenous Metabolite Adenylate Cyclase PKA Calcium Channel Neurological Disease Metabolic Disease
    Cerebellin is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin can be used in neurological research .
    Cerebellin
  • HY-159602
    BET BD2-IN-3

    		Epigenetic Reader Domain Cancer
    BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .
    BET BD2-IN-3
  • HY-101176R
    2-Iodomelatonin (Standard)

    		Reference Standards Melatonin Receptor Cancer
    2-Iodomelatonin (Standard) is the analytical standard of 2-Iodomelatonin. This product is intended for research and analytical applications. 2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 ?over MT2 . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .
    2-Iodomelatonin (Standard)
  • HY-B0415R
    Fluocinolone (Acetonide) (Standard)

    		Reference Standards Glucocorticoid Receptor Wnt Inflammation/Immunology Endocrinology
    Fluocinolone (Acetonide) (Standard) is the analytical standard of Fluocinolone (Acetonide). This product is intended for research and analytical applications. Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015) .
    Fluocinolone (Acetonide) (Standard)
  • HY-W777281
    Fluocinolone acetonide-13C3

    		Isotope-Labeled Compounds Glucocorticoid Receptor Wnt Endocrinology
    Fluocinolone acetonide- 13C3 is the 13C-labeled Fluocinolone (Acetonide) (HY-B0415). Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015) .
    Fluocinolone acetonide-13C3
  • HY-P1544A
    Cerebellin TFA

    		Calcium Channel PKA Endogenous Metabolite Adenylate Cyclase Neurological Disease Metabolic Disease
    Cerebellin TFA is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin TFA stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin TFA reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin TFA also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin TFA can be used in neurological research .
    Cerebellin TFA
  • HY-174723
    Human CXCR6 mRNA

    		mRNA Inflammation/Immunology
    Human CXCR6 mRNA encodes the human C-X-C motif chemokine receptor 6 (CXCR6) protein, a G protein-coupled receptor that belongs to the CXC chemokine receptor family. CXCR6 and its exclusive ligand, chemokine ligand 16 (CCL16), are part of a signalling pathway that regulates T lymphocyte migration to various peripheral tissues (the liver, spleen red pulp, intestine, lungs, and skin) and promotes cell-cell interaction with dendritic cells and fibroblastic reticular cells.
    Human CXCR6 mRNA
  • HY-182774
    YU241279

    		CXCR Cancer
    YU241279 is an orally active CXCR5 inhibitor. YU241279 inhibits CXCL13-mediated Gαq-dependent calcium influx and Gαi2-dependent cAMP reduction in CXCR5-expressing cells. YU241279 inhibits the proliferation of CXCR5-expressing lymphoma cells. YU241279 reduces tumor burden in the peripheral blood and bone marrow of mice implanted with lymphoma tissues. YU241279 is well tolerated during oral administration in mice, maintains stable plasma drug concentrations, and shows no metabolic changes. YU241279 can be used in the research of angioimmunoblastic T-cell lymphoma and Burkitt B-cell lymphoma .
    YU241279
  • HY-P1278B
    GR 64349 acetate

    		Neurokinin Receptor Neurological Disease Endocrinology
    GR 64349 acetate is a selective neurokinin 2 (NK2) receptor agonist. GR 64349 acetate selectively activates the NK-2 receptor subtype. GR 64349 acetate activates tonic and rhythmic bladder contractions of the micturition reflex. GR 64349 acetate does not inhibit rhythmic bladder contraction activation induced by normal saline. GR 64349 acetate induces inward currents .
    GR 64349 acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: